Detail akcie Moderna Rg online

Business Summary: Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Moderna Inc revenues decreased 64% to $6.85B. Net loss totaled $4.71B vs. income of $8.36B. Revenues reflect Europe segment decrease of 80% to $1.36B, Rest of the World segment decrease of 51% to $3.6B. Net loss reflects Research and development increase of 46% to $4.69B (expense), General and administrative increase of 38% to $1.44B (expense).